How Indian Pharma Companies Can Use AI for Schedule M Compliance

India's Union Ministry of Health and Family Welfare notified the revised Schedule M of the Drugs and Cosmetics Rules, 1945 in December 2023. The revision is a structural overhaul of Good Manufacturing Practice norms, bringing Indian GMP standards significantly closer to EU GMP and US FDA expectations. Large manufacturers were required to comply by June 2024. For MSMEs, the deadline was extended to December 2025, with manufacturers required to submit upgrade plans to the Central Licensing Approving Authority by May 2025.

The compliance situation is difficult. As of early 2025, only around 1,700 of an estimated 6,000 MSME drug manufacturers had submitted upgrade plans. Manufacturers who miss the deadline face licence cancellation and production shutdowns. The stakes could not be higher, and the clock is running. AI is not a substitute for the physical infrastructure upgrades Schedule M requires. But it addresses the documentation, data integrity, and process control gaps that account for a significant portion of compliance failures.

What the Revised Schedule M Requires

The revised Schedule M requirements cover a wide range of areas. Physical infrastructure and air handling system upgrades are the most visible. But the documentation and data management requirements are equally demanding, and often where manufacturers find themselves most exposed during inspections:

• Data integrity: All GMP data must meet ALCOA+ principles: Attributable, Legible, Contemporaneous, Original, Accurate, and also Complete, Consistent, Enduring, and Available. Paper-based systems and unvalidated spreadsheets typically cannot demonstrate this.
• Batch record completeness: Every batch must have a complete, retrievable record. Any modification to an entry must be traceable to the person who made it, with the original entry preserved.
• SOP management: All SOPs must be current, version-controlled, and accessible to relevant staff. Evidence of training against each SOP must be maintained.
• Deviation and CAPA management: Deviations must be recorded, investigated, and closed with documented corrective and preventive actions. The timeline from deviation identification to CAPA closure is subject to review.
• Audit trail requirements: Electronic systems used for GMP data must generate computer-generated, time-stamped audit trails. Operators cannot delete or overwrite records.

Where Manufacturers Are Most Exposed

Across Indian pharma manufacturers, the most common compliance gaps are not in physical infrastructure but in documentation systems. Batch records completed on paper, transcribed into spreadsheets, and stored in shared drives do not meet the audit trail requirements. SOP libraries that exist as PDFs in folder hierarchies without version control or training tracking are non-compliant. Deviation records managed through email threads or manual logs cannot demonstrate timely closure.

These are precisely the gaps that AI-powered systems address. And they are addressable faster and at lower cost than facility upgrades.

How AI Addresses Schedule M Documentation Requirements

Electronic batch records with audit trails: AI-assisted electronic batch record systems automatically generate time-stamped, attributable audit trails for every entry and modification. The original entry is always preserved. The system enforces the structure required by the batch record template, flagging incomplete entries before the record is released. Role-based access controls ensure that only authorised personnel can enter, review, or approve records for their respective stages.

SOP search and compliance tracking: AI document search makes the entire SOP library queryable in natural language. Staff can find the relevant SOP for any process in seconds, rather than navigating folder structures. The system can also track which staff have acknowledged each SOP revision, generating training completion records that are retrievable during inspections.

Deviation and CAPA management: AI-assisted deviation management systems create structured records at the point of deviation identification, automatically route them for investigation and approval, and track CAPA timelines against regulatory expectations. Inspectors can see a complete, timestamped record of every deviation and its resolution.

What Indian Pharma Manufacturers Should Do Now

With the December 2025 deadline approaching for MSMEs, the window for remediation is narrow. The practical sequence for manufacturers who have not yet addressed documentation compliance is: conduct a gap assessment against revised Schedule M documentation requirements, prioritise the gaps that represent the greatest inspection risk, and deploy electronic systems for batch records, SOP management, and deviation tracking before the deadline.

AI-powered systems for these functions can be deployed in weeks, not months. They do not require the capital expenditure of physical infrastructure upgrades, and they create an immediately auditable compliance record. For manufacturers already under pressure from the deadline, this is where AI delivers value most quickly.